This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Autoimmune disease				
Autoimmune disease	Calcium channel N-type; calcium channel P/Q-type	Cell-based and mouse studies identified an agonist of N- and P/Q-type calcium channels that could help treat Lambert-Eaton myasthenic syndrome. In cultured cells expressing N- or P/Q-type calcium channels, the roscovitine derivative GV-58 increased calcium conductance compared with vehicle control. In a mouse model for Lambert-Eaton myasthenic syndrome, GV-58 increased transmitter release from neuromuscular junctions compared with vehicle. Next steps include optimizing the compound and conducting tests in additional models for neuromuscular disorders.	Patent application filed; available for licensing	Tarr, T.B. <i>et al. J. Neurosci.</i> ; published online June 19, 2013; doi:10.1523/JNEUROSCI.4629-12.2013 Contact: Stephen D. Meriney, University of Pittsburgh, Pittsburgh, Pa. e-mail: meriney@pitt.edu Contact: Peter Wipf, same affiliation as above e-mail: pwipf@pitt.edu
<i>SciBX</i> 6(28); doi:10.1038/scibx.2013.713 Published online July 25, 2013				